COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | ¥30,978,000 | ¥30,978,000 | ¥24,454,000 | ¥23,797,000 |
| Dep. & Amort. | ¥22,229,000 | ¥22,229,000 | ¥19,924,000 | ¥17,368,000 |
| Deferred Tax | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock-Based Comp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Change in WC | -¥3,303,000 | -¥3,303,000 | ¥9,666,000 | ¥13,205,000 |
| Other Non-Cash | ¥2,563,000 | ¥2,563,000 | ¥1,131,000 | ¥64,000 |
| Operating Cash Flow | ¥52,467,000 | ¥52,467,000 | ¥55,175,000 | ¥54,434,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -¥53,326,000 | -¥53,326,000 | -¥55,810,000 | -¥46,636,000 |
| Net Acquisitions | ¥0 | ¥0 | ¥718,000 | ¥46,000 |
| Inv. Purchases | -¥558,000 | -¥558,000 | -¥523,000 | -¥500,000 |
| Inv. Sales/Matur. | ¥417,000 | ¥417,000 | ¥431,000 | ¥428,000 |
| Other Inv. Act. | -¥1,981,000 | -¥1,981,000 | -¥2,145,000 | -¥2,451,000 |
| Investing Cash Flow | -¥55,448,000 | -¥55,448,000 | -¥57,329,000 | -¥49,113,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | ¥12,680,000 | ¥12,680,000 | ¥13,187,000 | ¥6,514,000 |
| Stock Issued | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock Repurch. | -¥2,000 | -¥2,000 | ¥0 | -¥2,000 |
| Dividends Paid | -¥4,959,000 | -¥4,959,000 | -¥4,659,000 | -¥3,266,000 |
| Other Fin. Act. | -¥2,000 | -¥2,000 | -¥1,000 | -¥1,000 |
| Financing Cash Flow | ¥7,717,000 | ¥7,717,000 | ¥8,527,000 | ¥3,245,000 |
| Forex Effect | ¥1,000 | ¥1,000 | ¥0 | -¥1,000 |
| Net Chg. in Cash | ¥4,737,000 | ¥4,737,000 | ¥6,373,000 | ¥8,566,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | ¥52,301,000 | ¥52,301,000 | ¥45,928,000 | ¥37,362,000 |
| End Cash | ¥57,038,000 | ¥57,038,000 | ¥52,301,000 | ¥45,928,000 |
| Free Cash Flow | -¥859,000 | -¥859,000 | -¥635,000 | ¥7,798,000 |